Business Context and Reporting Period
Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Stage: Development Stage Company
Primary Activity: Developing and marketing a proprietary drug delivery system (Delcath System) for high-dose chemotherapy to treat liver cancer (specifically malignant melanoma metastasized to the liver). The company has no commercial revenues and relies on equity financing and interest income.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,057,746) | $(1,274,114) | Improvement of $216,368 |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.06) | Improvement |
| Total Costs & Expenses | $1,429,960 | $1,389,770 | Increase of $40,190 |
| Research & Development | $988,956 | $888,951 | Increase of $100,005 |
| General & Administrative | $441,004 | $500,819 | Decrease of $59,815 |
| Derivative Instrument Income | $198,251 | $0 | New Income Item |
| Interest Income | $173,963 | $115,656 | Increase of $58,307 |
| Cash & Cash Equivalents (End of Period) | $16,244,378 | $7,574,247 | Increase of $8,670,131 |
| Net Cash Used in Operating Activities | $(1,261,292) | $(1,917,070) | Decrease in usage of $655,778 |
| Derivative Liability | $1,353,749 | $1,552,000 | Decrease of $198,251 |
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss decreased by approximately 17% compared to Q1 2007. This improvement was primarily driven by a non-cash gain of $198,251 from the mark-to-market adjustment of derivative instrument liabilities (warrants issued in late 2007).
- Operating Expenses: Total operating costs increased slightly ($40,190). Research and Development (R&D) costs rose by 11.2% due to expenses for new filter technology. Conversely, General and Administrative (G&A) expenses fell by 12% due to reduced accounting fees and the resolution of prior legal matters.
- Liquidity Position: Cash and cash equivalents more than doubled from the prior year period, rising from $7.6 million to $16.2 million. This is largely due to the maturity of short-term investments (Treasury bills) and proceeds from a private placement in late 2007.
- Investment Activity: The company purchased $205,454 in short-term investments and $46,200 in restricted stock of Aethlon Medical, Inc. (AEMD) as part of an R&D agreement.
Outlook, Risks, and Management Commentary
- Clinical Progress: The company is actively conducting a Phase III clinical trial for the Delcath System using Melphalan for inoperable melanoma in the liver. In April 2008, the University of Maryland Medical Center approved participation, allowing patient recruitment to begin immediately.
- Capital Requirements: Management expects to continue incurring substantial losses for the next 12 months to fund Phase II and Phase III trials. The company has no assurance of achieving profitability and remains dependent on equity or debt financing.
- Legal Contingency: A libel lawsuit filed against the company and its former CEO was dismissed in 2007, but the defendant appealed the denial of sanctions. In March 2008, the Court of Appeals reversed the lower court's decision and remanded the case to determine appropriate sanctions. The defendant has claimed costs of $450,000, which the company disputes, but the final liability amount is uncertain.
- Derivative Liability: The company holds a liability of $1.35 million related to warrants issued in September 2007. Management believes the likelihood of cash settlement is remote and expects the liability to be credited to equity upon exercise or expiration.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $16.2 million cash balance against the projected burn rate for ongoing Phase III clinical trials.
- Legal Sanctions: Monitor the remanded proceedings regarding the libel lawsuit to determine the final financial impact of potential sanctions.
- Derivative Liability: Confirm the valuation assumptions (volatility, interest rates) used for the $1.35 million warrant liability and the potential for future mark-to-market volatility.
- Clinical Milestones: Track patient enrollment numbers and data readouts from the Phase III trial at the University of Maryland Medical Center.
- Financing Needs: Assess the timeline for potential future capital raises given the company's development stage status and lack of revenue.